Patents by Inventor Mavis D. Adam

Mavis D. Adam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenyl heterocyclyl ethers
    Patent number: 7129234
    Abstract: The invention relates to compounds of formula I
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: October 31, 2006
    Assignee: Pfizer Inc.
    Inventors: Mavis D. Adam, Mark D. Andrews, Geoffrey E. Gymer, David Hepworth, Harry R. Howard, Jr., Donald S. Middleton, Alan Stobie
  • Phenyl heterocyclyl ethers
    Publication number: 20040106594
    Abstract: The invention relates to compounds of formula I 1
    Type: Application
    Filed: November 25, 2003
    Publication date: June 3, 2004
    Applicant: Pfizer Inc
    Inventors: Mavis D. Adam, Mark D. Andrews, Geoffrey E. Gymer, David Hepworth, Harry R. Howard, Donald S. Middleton, Alan Stobie
  • Phenyl heterocyclyl ethers
    Publication number: 20030207857
    Abstract: The invention relates to compounds of formula I 1
    Type: Application
    Filed: April 11, 2002
    Publication date: November 6, 2003
    Inventors: Mavis D. Adam, Mark D. Andrews, Geoffrey E. Gymer, David Hepworth, Harry R. Howard, Donald S. Middleton, Alan Stobie
  • Biaryl ether derivatives useful as monoamine reuptake inhibitors
    Patent number: 6596741
    Abstract: The present invention relates to compounds of formula I: and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: July 22, 2003
    Assignee: Pfizer Inc
    Inventors: Harry R. Howard, Mavis D. Adam
  • Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
    Publication number: 20030083337
    Abstract: The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4(trifluoromethylphenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HT1D rector. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT1D receptor selective antagonist is therapeutically indicated.
    Type: Application
    Filed: August 9, 2002
    Publication date: May 1, 2003
    Inventors: Harry R. Howard, Stephane Caron, Mavis D. Adam
  • Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
    Publication number: 20030055038
    Abstract: The present invention relates to compounds of formula I, 1
    Type: Application
    Filed: May 22, 2002
    Publication date: March 20, 2003
    Applicant: Pfizer Inc.
    Inventors: Harry R. Howard, Mavis D. Adam
  • Biaryl ether derivatives useful as monoamine reuptake inhibitors
    Patent number: 6410736
    Abstract: The present invention relates to compounds of formula I, and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: June 25, 2002
    Assignee: Pfizer Inc.
    Inventors: Harry R. Howard, Jr., Mavis D. Adam